Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (symbol: PKI) is a leading global provider of solutions that enable scientists, researchers, and clinicians to tackle complex challenges in science and healthcare. The company's mission is to innovate for a healthier world through unique solutions that serve the diagnostics, life sciences, food, and applied markets.
PerkinElmer collaborates closely with its customers to deliver earlier and more accurate insights. This is supported by the company's deep market knowledge and technical expertise. With a dedicated workforce of approximately 14,000 employees worldwide, PerkinElmer is committed to improving the quality of life, creating healthier families, and sustaining the wellbeing and longevity of people globally.
In 2020, PerkinElmer reported revenues of approximately $3.8 billion and serves customers in 190 countries. Notably, the company is a component of the S&P 500 index, underscoring its significant market presence and financial stability.
Recent Achievements and Current Projects
- Strategic partnerships with key industry players to enhance diagnostic solutions and life sciences research.
- Continuous investment in innovative technologies and solutions that drive earlier and more accurate healthcare insights.
- Expansion of global reach through new product launches tailored to various market needs.
PerkinElmer's commitment to innovation and collaboration makes it a crucial player in the healthcare and scientific research sectors. By leveraging its extensive expertise and comprehensive solutions, the company strives to address the most pressing challenges faced by its customers.
Revvity (NYSE: RVTY) announced an expanded collaboration with Genomics England to advance genomic initiatives across the UK. The partnership focuses on the Generation Study, a research program aiming to screen up to 100,000 newborns for 200 rare genetic conditions in England. Through its Omics laboratory in Manchester, Revvity will extract DNA from cord blood samples using the chemagic 360™ instrument. The collaboration aims to advance early detection of genetic conditions in newborns while also supporting the development of genomics talent across the UK region.
Revvity (NYSE: RVTY) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference scheduled for December 3, 2024, at 8:20 a.m. ET in Coral Gables, FL. President and CEO Prahlad Singh will present an update on the company and its strategic priorities. The presentation will be accessible through a live audio webcast on the company's website's Events section, with a replay available on the Revvity Investor Relations website for at least 30 days following the event.
Scale Biosciences and Revvity's BioLegend (NYSE: RVTY) have launched the TotalSeq Phenocyte solution, a groundbreaking single-cell protein profiling technology. This innovation combines Scale Bio's Quantum Barcoding technology with BioLegend's TotalSeq antibody conjugates to enable more efficient identification and characterization of rare cell subtypes in immunology and oncology research.
The solution offers advantages over traditional methods like mass cytometry and flow cytometry by eliminating complex panel optimization and sophisticated instrumentation requirements, making it more accessible and scalable. It builds upon BioLegend's TotalSeq-A antibody panels and supports biomarker discovery without requiring dedicated instrumentation.
Revvity (NYSE: RVTY) has announced its upcoming Investor Day scheduled for November 21, 2024, at 9:00 a.m. PT. The company revealed strategic changes to its operating model, effective fiscal year 2025, including the integration of its Applied Genomics business into a new Life Sciences Solutions division.
The reorganization will result in two main reporting segments: Life Sciences (comprising Life Sciences Solutions and Software) and Diagnostics (including Immunodiagnostics and Reproductive Health). This restructuring aims to enhance operational efficiency, create synergies, and improve customer service delivery.
Revvity reported strong Q3 2024 financial results with revenue reaching $684 million, representing 2% reported and organic growth. GAAP EPS was $0.77, while adjusted EPS from continuing operations reached $1.28. The company's Diagnostics segment showed 6% growth with $383 million revenue, while Life Sciences recorded $301 million, a 2% decrease. Operating margins improved, with GAAP operating profit margin at 14.3% and adjusted operating profit margin at 28.3%. The company raised its full-year 2024 adjusted EPS guidance to $4.83-$4.87 and announced a new $1 billion share repurchase program.
Revvity (NYSE: RVTY) announced that its Board of Directors has declared a quarterly dividend of $0.07 per share of common stock. The dividend will be paid on February 7, 2025, to shareholders of record as of the close of business on January 17, 2025.
Revvity, Inc. (NYSE: RVTY) has launched Revvity Transcribe AI, an innovative optical character recognition (OCR) service that converts handwritten text on test request forms into digital format. This solution aims to streamline workflows and reduce manual data entry tasks in clinical laboratories. Key features include:
- 40% improvement in overall data entry workflow speed, including data validation
- Especially valuable for newborn screening (NBS) laboratories
- Compatible with Revvity's EVOYA™ platform for NBS software
- Secure data processing with ISO27001 compliance
The service allows laboratory personnel to focus on other essential tasks by automating the manually intensive process of transcribing handwritten information. Revvity Transcribe AI will be introduced at the 2024 APHL Newborn Screening Symposium in Omaha, Nebraska.
Revvity, Inc. (NYSE: RVTY) has released its annual Impact Report, showcasing the company's sustainability, social, and governance initiatives. Key highlights include:
- A 7% reduction in Scope 1 and 2 emissions in 2023
- Implementation of a sustainability due diligence program for suppliers
- 75% employee satisfaction with 85% participation in a survey
- Maintained 40% female representation in leadership positions
- Expanded gender pay gap analysis
- Introduction of new corporate policies on ethical AI, sustainable procurement, and cyber risk management
- Creation of Revvity Access STEM Scholarships
CEO Prahlad Singh emphasized the company's commitment to creating a healthier, cleaner, and more inclusive world through innovative solutions and sustainability initiatives.
Revvity, Inc. (NYSE: RVTY) has announced its plans to release third quarter 2024 financial results before the market opens on Monday, November 4, 2024. The company will host a conference call at 8:00 a.m. ET on the same day to discuss these results. Prahlad Singh, president and CEO, and Max Krakowiak, CFO, will lead the conference call. Investors can access a live audio webcast of the call through the Investors section of Revvity's website.
Revvity (NYSE: RVTY) has announced the launch of the EURORealTime APOE assay, an in-vitro diagnostic test for APOE genotyping in European countries accepting the CE mark. This test is important for assessing a patient's risk of side effects before starting anti-amyloid therapy for Alzheimer's disease.
The assay allows simultaneous detection of the three most frequent APOE forms (E2, E3, and E4), with E4 carriers having the highest risk for ARIA (Amyloid-Related Imaging Abnormalities) under therapy. The test requires only one reaction using genomic DNA from a single blood sample and can be automated on Revvity instruments, including the EUROIMMUN PreNAT II and chemagic 360 platforms.
This new solution will enable clinicians to take a more personalized approach in anti-amyloid treatment for Alzheimer's patients by providing additional patient information through APOE genotyping.
FAQ
What is the market cap of PERKINELMER (PKI)?
What does PerkinElmer Inc. do?
What is the mission of PerkinElmer Inc.?
How many employees does PerkinElmer Inc. have?
What was PerkinElmer Inc.'s revenue in 2020?
In how many countries does PerkinElmer Inc. serve customers?
What are some of PerkinElmer Inc.'s recent achievements?
How does PerkinElmer Inc. contribute to healthcare?
Is PerkinElmer Inc. part of any major stock index?
What markets does PerkinElmer Inc. serve?
What is a core focus of PerkinElmer Inc.'s partnerships?
